Amgen (AMGN) 10-Q 29 Jul 20 2020 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2020	Jul. 23, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	001-37702
Entity Registrant Name	Amgen Inc.
Entity Central Index Key	0000318154
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-3540776
Entity Address, Address Line One	One Amgen Center Drive
Entity Address, City or Town	Thousand Oaks
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91320-1799
City Area Code	805
Local Phone Number	447-1000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		585,693,775
The NASDAQ Global Select Market [Member] | Common Stock [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value
Trading Symbol	AMGN
Security Exchange Name	NASDAQ
New York Stock Exchange [Member] | 1.250% Senior Notes Due 2022 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes Due 2022
Trading Symbol	AMGN22
Security Exchange Name	NYSE
New York Stock Exchange [Member] | 2.00% Senior Notes Due 2026 [Member]
Entity Information [Line Items]
Title of 12(b) Security	2.00% Senior Notes Due 2026
Trading Symbol	AMGN26
Security Exchange Name	NYSE

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 1,803	$ 2,179	$ 3,628	$ 4,171
Other comprehensive (loss) income, net of reclassification adjustments and taxes:
Losses on foreign currency translation	(3)	(4)	(55)	(17)
Losses on cash flow hedges	(116)	(104)	(177)	(59)
(Losses) gains on available-for-sale securities	(2)	153	(21)	374
Other	0	6	(2)	6
Other comprehensive (loss) income, net of taxes	(121)	51	(255)	304
Comprehensive income	$ 1,682	$ 2,230	$ 3,373	$ 4,475

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Total revenues	$ 6,206	$ 5,871	$ 12,367	$ 11,428
Operating expenses:
Cost of sales	1,488	1,012	3,001	2,067
Research and development	964	924	1,916	1,803
Selling, general and administrative	1,295	1,260	2,611	2,414
Other	136	(3)	161	(6)
Total operating expenses	3,883	3,193	7,689	6,278
Operating income	2,323	2,678	4,678	5,150
Interest expense, net	296	332	642	675
Interest and other income, net	3	218	14	403
Income before income taxes	2,030	2,564	4,050	4,878
Provision for income taxes	227	385	422	707
Net income	$ 1,803	$ 2,179	$ 3,628	$ 4,171
Earnings per share:
Basic (in usd per share)	$ 3.07	$ 3.59	$ 6.16	$ 6.78
Diluted (in usd per share)	$ 3.05	$ 3.57	$ 6.12	$ 6.75
Shares used in calculation of earnings per share:
Basic (in shares)	588	607	589	615
Diluted (in shares)	592	610	593	618
Product sales [Member]
Revenues:
Product sales	$ 5,908	$ 5,574	$ 11,802	$ 10,860
Other revenues [Member]
Revenues:
Total revenues	$ 298	$ 297	$ 565	$ 568

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 9,145	$ 6,037
Marketable securities	2,276	2,874
Trade receivables, net	5,366	4,057
Inventories	3,840	3,584
Other current assets	2,268	1,888
Total current assets	22,895	18,440
Property, plant and equipment, net	4,843	4,928
Intangible assets, net	17,948	19,413
Goodwill	14,678	14,703
Other assets	4,647	2,223
Total assets	65,011	59,707
Current liabilities:
Accounts payable	1,150	1,371
Accrued liabilities	9,282	8,511
Current portion of long-term debt	91	2,953
Total current liabilities	10,523	12,835
Long-term debt	34,133	26,950
Long-term deferred tax liabilities	259	606
Long-term tax liabilities	7,556	8,037
Other noncurrent liabilities	1,881	1,606
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 586.4 shares in 2020 and 591.4 shares in 2019	31,610	31,531
Accumulated deficit	(20,168)	(21,330)
Accumulated other comprehensive loss	(783)	(528)
Total stockholders’ equity	10,659	9,673
Total liabilities and stockholders’ equity	$ 65,011	$ 59,707

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock and additional paid-in capital, shares authorized	2,750	2,750
Common stock and additional paid-in capital, shares outstanding	586.4	591.4

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Number of shares of common stock [Member]	Common stock and additional paid-in capital [Member]	Accumulated deficit [Member]	Accumulated other comprehensive loss [Member]
Beginning Balance, Shares at Dec. 31, 2018		629.6
Balance as of beginning of period at Dec. 31, 2018	$ 12,500		$ 31,246	$ (17,977)	$ (769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	1,992			1,992
Other comprehensive income (loss), net of taxes	253				253
Dividends declared on common stock	(879)			(879)
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.7
Issuance of common stock in connection with the Company’s equity award programs	6		6
Stock-based compensation expense	64		64
Tax impact related to employee stock-based compensation expense	(73)		(73)
Repurchases of common stock, Shares		(15.9)
Repurchases of common stock	(3,031)			(3,031)
Ending Balance, Shares at Mar. 31, 2019		614.4
Balance as of end of period at Mar. 31, 2019	10,832		31,243	(19,895)	(516)
Beginning Balance, Shares at Dec. 31, 2018		629.6
Balance as of beginning of period at Dec. 31, 2018	12,500		31,246	(17,977)	(769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	4,171
Ending Balance, Shares at Jun. 30, 2019		602.1
Balance as of end of period at Jun. 30, 2019	10,794		31,313	(20,054)	(465)
Beginning Balance, Shares at Mar. 31, 2019		614.4
Balance as of beginning of period at Mar. 31, 2019	10,832		31,243	(19,895)	(516)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	2,179			2,179
Other comprehensive income (loss), net of taxes	51				51
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.8
Issuance of common stock in connection with the Company’s equity award programs	23		23
Stock-based compensation expense	97		97
Tax impact related to employee stock-based compensation expense	(50)		(50)
Repurchases of common stock, Shares		(13.1)
Repurchases of common stock	(2,349)			(2,349)
Other	11			11
Ending Balance, Shares at Jun. 30, 2019		602.1
Balance as of end of period at Jun. 30, 2019	10,794		31,313	(20,054)	(465)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of changes in accounting principles, net of taxes	$ (2)			(2)
Beginning Balance, Shares at Dec. 31, 2019	591.4	591.4
Balance as of beginning of period at Dec. 31, 2019	$ 9,673		31,531	(21,330)	(528)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	1,825			1,825
Other comprehensive income (loss), net of taxes	(134)				(134)
Dividends declared on common stock	(938)			(938)
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.9
Issuance of common stock in connection with the Company’s equity award programs	10		10
Stock-based compensation expense	52		52
Tax impact related to employee stock-based compensation expense	(68)		(68)
Repurchases of common stock, Shares		(4.3)
Repurchases of common stock	(933)			(933)
Ending Balance, Shares at Mar. 31, 2020		588
Balance as of end of period at Mar. 31, 2020	$ 9,485		31,525	(21,378)	(662)
Beginning Balance, Shares at Dec. 31, 2019	591.4	591.4
Balance as of beginning of period at Dec. 31, 2019	$ 9,673		31,531	(21,330)	(528)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	$ 3,628
Ending Balance, Shares at Jun. 30, 2020	586.4	586.4
Balance as of end of period at Jun. 30, 2020	$ 10,659		31,610	(20,168)	(783)
Beginning Balance, Shares at Mar. 31, 2020		588
Balance as of beginning of period at Mar. 31, 2020	9,485		31,525	(21,378)	(662)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	1,803			1,803
Other comprehensive income (loss), net of taxes	(121)				(121)
Issuance of common stock in connection with the Company’s equity award programs, Shares		1
Issuance of common stock in connection with the Company’s equity award programs	65		65
Stock-based compensation expense	101		101
Tax impact related to employee stock-based compensation expense	(81)		(81)
Repurchases of common stock, Shares		(2.6)
Repurchases of common stock	(591)			(591)
Other	$ (2)			(2)
Ending Balance, Shares at Jun. 30, 2020	586.4	586.4
Balance as of end of period at Jun. 30, 2020	$ 10,659		$ 31,610	$ (20,168)	$ (783)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	1 Months Ended		3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Statement of Stockholders' Equity [Abstract]
Common stock, dividends declared per share (in usd per share)	$ 1.60	$ 1.60	$ 1.60	$ 1.45

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net income	$ 3,628	$ 4,171
Depreciation, amortization and other	1,827	996
Deferred income taxes	(261)	(70)
Other items, net	245	32
Changes in operating assets and liabilities, net of acquisition:
Trade receivables, net	(1,177)	(228)
Inventories	(226)	(118)
Other assets	143	(158)
Accounts payable	(216)	(205)
Accrued income taxes, net	452	(257)
Long-term tax liabilities	106	(322)
Other liabilities	455	(582)
Net cash provided by operating activities	4,976	3,259
Cash flows from investing activities:
Purchases of marketable securities	(2,229)	(7,250)
Proceeds from sales of marketable securities	2,598	217
Proceeds from maturities of marketable securities	238	13,617
Purchases of property, plant and equipment	(300)	(260)
Purchases of equity method investments	(2,648)	(12)
Other	(48)	(12)
Net cash (used in) provided by investing activities	(2,389)	6,300
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt	9,002	0
Repayment of debt	(5,000)	(3,650)
Repurchases of common stock	(1,516)	(5,447)
Dividends paid	(1,887)	(1,781)
Other	(78)	(101)
Net cash provided by (used in) financing activities	521	(10,979)
Increase (decrease) in cash and cash equivalents	3,108	(1,420)
Cash and cash equivalents at beginning of period	6,037	6,945
Cash and cash equivalents at end of period	$ 9,145	$ 5,525

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics. Basis of presentation The financial information for the three and six months ended June 30, 2020 and 2019, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2019, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2020. Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.7 billion and $8.4 billion as of June 30, 2020 and December 31, 2019, respectively. Equity method investments The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Condensed Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value. Recent accounting pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our condensed consolidated financial statements. In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022, as a result of reference rate reform. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.

Revenues

Revenues	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenues	Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe. Revenues were as follows (in millions): Three months ended June 30, 2020 2019 US ROW Total US ROW Total Enbrel ® (etanercept) $ 1,213 $ 33 $ 1,246 $ 1,315 $ 48 $ 1,363 Prolia ® (denosumab) 441 218 659 458 240 698 Neulasta ® (pegfilgrastim) 520 73 593 719 105 824 Otezla ® (apremilast) 464 97 561 — — — XGEVA ® (denosumab) 318 117 435 379 120 499 Aranesp ® (darbepoetin alfa) 156 231 387 192 244 436 KYPROLIS ® (carfilzomib) 167 86 253 166 101 267 Repatha ® (evolocumab) 115 85 200 91 61 152 Other products 1,034 540 1,574 822 513 1,335 Total product sales (1) $ 4,428 $ 1,480 5,908 $ 4,142 $ 1,432 5,574 Other revenues 298 297 Total revenues $ 6,206 $ 5,871 Six months ended June 30, 2020 2019 US ROW Total US ROW Total ENBREL $ 2,330 $ 69 $ 2,399 $ 2,421 $ 93 $ 2,514 Prolia ® 863 450 1,313 848 442 1,290 Neulasta ® 1,054 148 1,202 1,612 233 1,845 Otezla ® 841 199 1,040 — — — XGEVA ® 673 243 916 735 235 970 Aranesp ® 331 478 809 374 476 850 KYPROLIS ® 354 179 533 320 192 512 Repatha ® 239 190 429 174 119 293 Other products 2,022 1,139 3,161 1,649 937 2,586 Total product sales (1) $ 8,707 $ 3,095 11,802 $ 8,133 $ 2,727 10,860 Other revenues 565 568 Total revenues $ 12,367 $ 11,428 ____________

Income taxes

Income taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The effective tax rates for the three and six months ended June 30, 2020, were 11.2% and 10.4%, respectively, compared with 15.0% and 14.5%, respectively, for the corresponding periods of the prior year. The decrease in our effective tax rate for the three and six months ended June 30, 2020, was due primarily to net favorable items in the quarter, amortization related to the Otezla ® acquisition and changes in jurisdictional mix of earnings. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes and are subject to tax incentive grants through 2035. In addition, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. These earnings are also subject to U.S. tax at a reduced rate of 10.5%. The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. As previously disclosed, we received a Revenue Agent Report (RAR) from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012. The RAR proposes to make significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculations but continued to propose substantial adjustments. We disagree with the proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If unable to reach resolution, we will vigorously contest the proposed adjustments through the judicial process. In addition, as previously reported, in April 2020, we received draft notices of proposed adjustments (NOPAs) and subsequently in May 2020, we received an RAR from the IRS for the years 2013, 2014 and 2015, which are similar to the proposed adjustments for the years 2010, 2011 and 2012 that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagree with the proposed adjustments and calculations and will pursue resolution with the IRS administrative appeals office. We are also currently under examination by a number of other state and foreign tax jurisdictions. Final resolution of these complex matters is not likely within the next 12 months and could have a material impact on our condensed consolidated financial statements. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes, the ultimate resolution of any tax matters may result in payments substantially greater or less than amounts accrued. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. During the three and six months ended June 30, 2020, the gross amounts of our unrecognized tax benefits (UTBs) increased $55 million and $105 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of June 30, 2020, if recognized, would affect our effective tax rate.

Earnings per share

Earnings per share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Earnings per share	Earnings per share The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method. The computations for basic and diluted EPS were as follows (in millions, except per-share data): Three months ended Six months ended 2020 2019 2020 2019 Income (Numerator): Net income for basic and diluted EPS $ 1,803 $ 2,179 $ 3,628 $ 4,171 Shares (Denominator): Weighted-average shares for basic EPS 588 607 589 615 Effect of dilutive securities 4 3 4 3 Weighted-average shares for diluted EPS 592 610 593 618 Basic EPS $ 3.07 $ 3.59 $ 6.16 $ 6.78 Diluted EPS $ 3.05 $ 3.57 $ 6.12 $ 6.75 For the three and six months ended June 30, 2020 and 2019, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

Collaborations

Collaborations	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations	Collaborations On January 2, 2020, we closed our strategic collaboration with BeiGene, Ltd. (BeiGene) to expand our oncology presence in China. Under the collaboration, BeiGene will commercialize XGEVA ® , KYPROLIS ® and BLINCYTO ® (blinatumomab) in China, and Amgen will share profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China. In addition, we will jointly develop a portion of our oncology portfolio with BeiGene sharing in global research and development (R&D) costs by providing cash and development services up to $1.25 billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will also pay BeiGene royalties. For the three and six months ended June 30, 2020, net costs recovered from BeiGene for oncology product candidates were $55 million and $112 million, respectively, and were recorded in R&D expense in the Condensed Consolidated Statements of Income. For the six months ended June 30, 2020, no profit share payments or product sales were recorded between Amgen and BeiGene. In connection with this collaboration, we acquired an ownership interest in BeiGene. See Note 6, Investments.

Investments

Investments	6 Months Ended
	Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Available-for-sale investments The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of June 30, 2020 Amortized Gross Gross Fair U.S. Treasury notes $ 172 $ 3 $ — $ 175 U.S. Treasury bills 3,399 — — 3,399 Corporate debt securities: Financial — — — — Industrial 3 — (1) 2 Other — — — — Residential-mortgage-backed securities — — — — Money market mutual funds 7,158 — — 7,158 Other short-term interest-bearing securities — — — — Total interest-bearing securities $ 10,732 $ 3 $ (1) $ 10,734 Types of securities as of December 31, 2019 Amortized Gross Gross Fair U.S. Treasury notes $ 359 $ 1 $ — $ 360 U.S. Treasury bills — — — — Corporate debt securities: Financial 1,108 13 — 1,121 Industrial 824 10 — 834 Other 195 3 — 198 Residential-mortgage-backed securities 181 1 — 182 Money market mutual funds 5,250 — — 5,250 Other short-term interest-bearing securities 289 — — 289 Total interest-bearing securities $ 8,206 $ 28 $ — $ 8,234 The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions): Condensed Consolidated Balance Sheets locations June 30, 2020 December 31, 2019 Cash and cash equivalents $ 8,458 $ 5,360 Marketable securities 2,276 2,874 Total interest-bearing securities $ 10,734 $ 8,234 Cash and cash equivalents in the above table excludes bank account cash of $687 million and $677 million as of June 30, 2020 and December 31, 2019, respectively. The fair values of interest-bearing securities by contractual maturity, except for residential-mortgage-backed securities that do not have a single maturity date, were as follows (in millions): Contractual maturities June 30, 2020 December 31, 2019 Maturing in one year or less $ 10,681 $ 5,629 Maturing after one year through three years 53 2,304 Maturing after three years through five years — 119 Residential-mortgage-backed securities — 182 Total interest-bearing securities $ 10,734 $ 8,234 For the three months ended June 30, 2020 and 2019, realized gains and losses on interest-bearing securities were not material. For the six months ended June 30, 2020 and 2019, realized gains on interest-bearing securities were $37 million and $2 million, respectively, and realized losses on interest-bearing securities were $4 million and $8 million, respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. As of June 30, 2020 and December 31, 2019, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, no allowance for credit losses was recorded as of June 30, 2020. Equity securities We held investments in equity securities with readily determinable fair values of $297 million and $303 million as of June 30, 2020 and December 31, 2019, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Gains and losses recognized on equity securities with readily determinable fair values, including gains and losses recognized on sales, were not material for the three and six months ended June 30, 2020 and 2019. We held investments of $183 million and $176 million in equity securities without readily determinable fair values as of June 30, 2020 and December 31, 2019, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Gains and losses recognized on these securities, including adjustments to the carrying values of these securities, were not material for the three and six months ended June 30, 2020 and 2019. Equity method investments Limited partnerships We held limited partnership investments of $311 million and $320 million as of June 30, 2020 and December 31, 2019, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of June 30, 2020, unfunded additional commitments to be made for these investments during the next several years were not material. Gains and losses recognized from our limited partnership investments were not material for the three and six months ended June 30, 2020 and 2019. BeiGene On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8 billion, of which $2.6 billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&D. Our equity investment in BeiGene is included in Other assets in the Condensed Consolidated Balance Sheets. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net assets of BeiGene by approximately $2.4 billion. This investment is accounted for by using the equity method of accounting, which requires us to identify and allocate amounts to the items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, are included in Interest and other income, net, in our Condensed Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from 8 to 15 years. For the three and six months ended June 30, 2020, we recognized a reduction in the carrying value of our investment of $111 million. This reduction consists of our share of BeiGene’s net loss, totaling $75 million, and amortization of the basis difference of $36 million. As of June 30, 2020, the carrying and fair values of our approximately 20.4% ownership interest in BeiGene totaled $2.5 billion and $3.0 billion, respectively. As of June 30, 2020, we believe the carrying value of our equity investment in BeiGene is fully recoverable. See Note 1, Summary of significant accounting policies, for factors considered in determi ning our conclusion. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 5, Collaborations. On July 15, 2020 , in connection with BeiGene’s equity offering, Amgen made an additional investment of approximately $421 million

Inventories

Inventories	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in millions): June 30, 2020 December 31, 2019 Raw materials $ 463 $ 358 Work in process 2,376 2,227 Finished goods 1,001 999 Total inventories $ 3,840 $ 3,584

Goodwill and other intangible a

Goodwill and other intangible assets	6 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Goodwill The change in the carrying amount of goodwill was as follows (in millions): Six months ended Beginning balance $ 14,703 Currency translation adjustment (25) Ending balance $ 14,678 Other intangible assets Other intangible assets consisted of the following (in millions): June 30, 2020 December 31, 2019 Gross Accumulated Other intangible Gross Accumulated Other intangible Finite-lived intangible assets: Developed-product-technology rights $ 25,559 $ (9,436) $ 16,123 $ 25,575 $ (8,322) $ 17,253 Licensing rights 3,746 (2,602) 1,144 3,761 (2,398) 1,363 Marketing-related rights 1,371 (1,003) 368 1,382 (965) 417 Research and development technology rights 1,279 (996) 283 1,273 (947) 326 Total finite-lived intangible assets 31,955 (14,037) 17,918 31,991 (12,632) 19,359 Indefinite-lived intangible assets: In-process research and development 30 — 30 54 — 54 Total other intangible assets $ 31,985 $ (14,037) $ 17,948 $ 32,045 $ (12,632) $ 19,413 Developed-product-technology rights consists of rights related to marketed products. Licensing rights consists primarily of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses. In-process research and development (IPR&D) consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval. During the three months ended June 30, 2020 and 2019, we recognized amortization associated with our finite-lived intangible assets of $713 million and $315 million, respectively. During the six months ended June 30, 2020 and 2019, we recognized amortization associated with our finite-lived intangible assets of $1.4 billion and $630 million, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining six months ending December 31, 2020, and the years ending December 31, 2021, 2022, 2023, 2024 and 2025, are $1.4 billion, $2.6 billion, $2.5 billion, $2.4 billion, $2.4 billion and $2.2 billion, respectively.

Financing arrangements

Financing arrangements	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Financing arrangements	Financing arrangements Our borrowings consisted of the following (in millions): June 30, 2020 December 31, 2019 4.50% notes due 2020 (4.50% 2020 Notes) $ — $ 300 2.125% notes due 2020 (2.125% 2020 Notes) — 750 Floating Rate Notes due 2020 — 300 2.20% notes due 2020 (2.20% 2020 Notes) — 700 3.45% notes due 2020 (3.45% 2020 Notes) — 900 4.10% notes due 2021 (4.10% 2021 Notes) — 1,000 1.85% notes due 2021 (1.85% 2021 Notes) — 750 3.875% notes due 2021 (3.875% 2021 Notes) 1,450 1,750 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) 1,404 1,402 2.70% notes due 2022 (2.70% 2022 Notes) 500 500 2.65% notes due 2022 (2.65% 2022 Notes) 1,500 1,500 3.625% notes due 2022 (3.625% 2022 Notes) 750 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 739 725 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 1.90% notes due 2025 (1.90% 2025 Notes) 500 — 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 843 841 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 589 630 2.20% notes due 2027 (2.20% 2027 Notes) 1,750 — 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 868 928 2.45% notes due 2030 (2.45% 2030 Notes) 1,250 — 2.30% notes due 2031 (2.30% 2031 Notes) 1,250 — 6.375% notes due 2037 (6.375% 2037 Notes) 552 552 6.90% notes due 2038 (6.90% 2038 Notes) 291 291 6.40% notes due 2039 (6.40% 2039 Notes) 466 466 3.15% notes due 2040 (3.15% 2040 Notes) 2,000 — 5.75% notes due 2040 (5.75% 2040 Notes) 412 412 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 974 974 5.65% notes due 2042 (5.65% 2042 Notes) 487 487 5.375% notes due 2043 (5.375% 2043 Notes) 261 261 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 3.375% notes due 2050 (3.375% 2050 Notes) 2,250 — 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (849) (868) Fair value adjustments 678 296 Other 3 — Total carrying value of debt 34,224 29,903 Less current portion (91) (2,953) Total long-term debt $ 34,133 $ 26,950 There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes and the 4.663% 2051 Notes, which have effective interest rates of 6.3% and 5.6%, respectively. Debt issuances and repayments During the six months ended June 30, 2020, we issued debt securities in the following offerings: • In February 2020, we issued $5.0 billion of debt consisting of $500 million of the 1.90% 2025 Notes, $750 million of the 2.20% 2027 Notes, $1.25 billion of the 2.45% 2030 Notes, $1.25 billion of the 3.15% 2040 Notes and $1.25 billion of the 3.375% 2050 Notes. • In May 2020, we issued $4.0 billion of debt, including $1.0 billion of the 2.20% 2027 Notes, $750 million of the 3.15% 2040 Notes and $1.0 billion of the 3.375% 2050 Notes, which represents a further issuance of, and which forms a single series with, each of the corresponding series of notes issued in February 2020, and $1.25 billion of 2.30% 2031 Notes. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a “make-whole” amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during specified periods of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity. A portion of the proceeds from the issuance of the notes in February 2020 were used to redeem the 3.45% 2020 Notes, the 4.10% 2021 Notes, the 1.85% 2021 Notes and the $300 million aggregate principal amount of our 3.875% 2021 Notes. In connection with the redemption of these notes, we paid a total of $50 million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Condensed Consolidated Statements of Income. In addition to these redemptions, the 4.50% 2020 Notes, 2.125% 2020 Notes, Floating Rate 2020 Notes and 2.20% 2020 Notes matured and were repaid during the six months ended June 30, 2020. Interest rate swaps In connection with the redemption of certain of the notes discussed above, associated interest rate swap contracts with an aggregate notional value of $2.2 billion were terminated. In addition, because of historically low interest rates, during the three months ended March 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2 billion that hedged the 3.625% 2024 Notes, the 2.60% 2026 Notes, the 4.663% 2051 Notes and portions of the 3.625% 2022 Notes and 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 12, Derivative instruments. The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions): June 30, 2020 December 31, 2019 Notes Notional amounts Effective interest rates Notional amounts Effective interest rates 3.45% 2020 Notes $ — LIBOR + 1.1% $ 900 LIBOR + 1.1% 4.10% 2021 Notes — LIBOR + 1.7% 1,000 LIBOR + 1.7% 3.875% 2021 Notes 1,450 LIBOR + 2.0% 1,750 LIBOR + 2.0% 3.625% 2022 Notes 750 LIBOR + 2.7% 750 LIBOR + 1.6% 3.625% 2024 Notes 1,400 LIBOR + 3.2% 1,400 LIBOR + 1.4% 3.125% 2025 Notes 1,000 LIBOR + 1.8% 1,000 LIBOR + 0.9% 2.60% 2026 Notes 1,250 LIBOR + 1.8% 1,250 LIBOR + 0.3% 4.663% 2051 Notes (1) 1,500 LIBOR + 2.6% 1,500 LIBOR + 0.0% Total notional amounts $ 7,350 $ 9,550 ____________ (1) Excludes an additional 1.5% of interest for the difference between the coupon rate paid to note holders and the fixed rate received under the interest rate swap contracts.

Stockholders' equity

Stockholders' equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders' equity	Stockholders’ equity Stock repurchase program Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): 2020 2019 Shares Dollars Shares * Dollars First quarter 4.3 $ 933 15.9 $ 3,031 Second quarter 2.6 591 13.1 2,349 Total stock repurchases 6.9 $ 1,524 28.9 $ 5,380 * Total shares do not add due to rounding. In December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $4.0 billion. As of June 30, 2020, $4.9 billion of authorization remained available under our stock repurchase program. Dividends In March 2020 and December 2019, the Board of Directors declared quarterly cash dividends of $1.60 per share, which were paid in June 2020 and March 2020, respectively. In July 2020, the Board of Directors declared a quarterly dividend of $1.60 per share, which will be paid on September 8, 2020. Accumulated other comprehensive income (loss) The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions): Foreign Cash flow Available-for-sale Other AOCI Balance as of December 31, 2019 $ (718) $ 175 $ 22 $ (7) $ (528) Foreign currency translation adjustments (52) — — — (52) Unrealized (losses) gains — (162) 8 — (154) Reclassification adjustments to income — 84 (33) — 51 Other — — — (2) (2) Income taxes — 17 6 — 23 Balance as of March 31, 2020 (770) 114 3 (9) (662) Foreign currency translation adjustments (3) — — — (3) Unrealized losses — (30) (2) — (32) Reclassification adjustments to income — (119) — — (119) Other — — — — — Income taxes — 33 — — 33 Balance as of June 30, 2020 $ (773) $ (2) $ 1 $ (9) $ (783) Reclassifications out of AOCI and into earnings were as follows (in millions): Three months ended June 30, Components of AOCI 2020 2019 Condensed Consolidated Cash flow hedges: Foreign currency contract gains $ 68 $ 22 Product sales Cross-currency swap contract gains 51 14 Interest and other income, net 119 36 Income before income taxes (26) (8) Provision for income taxes $ 93 $ 28 Net income Available-for-sale securities: Net realized losses $ — $ (2) Interest and other income, net — — Provision for income taxes $ — $ (2) Net income Six months ended June 30, Components of AOCI 2020 2019 Condensed Consolidated Cash flow hedges: Foreign currency contract gains $ 117 $ 36 Product sales Cross-currency swap contract losses (82) (28) Interest and other income, net 35 8 Income before income taxes (8) (2) Provision for income taxes $ 27 $ 6 Net income Available-for-sale securities: Net realized gains (losses) $ 33 $ (6) Interest and other income, net (7) — Provision for income taxes $ 26 $ (6) Net income

Fair value measurement

Fair value measurement	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 — Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement. The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Quoted prices in Significant Significant Fair value measurement as of June 30, 2020, using: Total Assets: Available-for-sale securities: U.S. Treasury notes $ 175 $ — $ — $ 175 U.S. Treasury bills 3,399 — — 3,399 Corporate debt securities: Financial — — — — Industrial — 2 — 2 Other — — — — Residential-mortgage-backed securities — — — — Money market mutual funds 7,158 — — 7,158 Other short-term interest-bearing securities — — — — Equity securities 297 — — 297 Derivatives: Foreign currency contracts — 236 — 236 Cross-currency swap contracts — 27 — 27 Interest rate swap contracts — 121 — 121 Total assets $ 11,029 $ 386 $ — $ 11,415 Liabilities: Derivatives: Foreign currency contracts $ — $ 26 $ — $ 26 Cross-currency swap contracts — 604 — 604 Interest rate swap contracts — 2 — 2 Contingent consideration obligations — — 55 55 Total liabilities $ — $ 632 $ 55 $ 687 Quoted prices in Significant Significant Fair value measurement as of December 31, 2019, using: Total Assets: Available-for-sale securities: U.S. Treasury notes $ 360 $ — $ — $ 360 U.S. Treasury bills — — — — Corporate debt securities: Financial — 1,121 — 1,121 Industrial — 834 — 834 Other — 198 — 198 Residential-mortgage-backed securities — 182 — 182 Money market mutual funds 5,250 — — 5,250 Other short-term interest-bearing securities — 289 — 289 Equity securities 303 — — 303 Derivatives: Foreign currency contracts — 224 — 224 Cross-currency swap contracts — 66 — 66 Interest rate swap contracts — 259 — 259 Total assets $ 5,913 $ 3,173 $ — $ 9,086 Liabilities: Derivatives: Foreign currency contracts $ — $ 31 $ — $ 31 Cross-currency swap contracts — 315 — 315 Interest rate swap contracts — — — — Contingent consideration obligations — — 61 61 Total liabilities $ — $ 346 $ 61 $ 407 Interest-bearing and equity securities The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment. As of June 30, 2020, our corporate debt securities are not material. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs. Derivatives All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by Standard & Poor’s Financial Services LLC (S&P), Moody’s Investors Service, Inc. (Moody’s) or Fitch Ratings, Inc. (Fitch). We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments. Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments. Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments. During the three and six months ended June 30, 2020 and 2019, there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis. Summary of the fair values of other financial instruments Cash equivalents The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. Borrowings We estimated the fair values of our borrowings by using Level 2 inputs. As of June 30, 2020 and December 31, 2019, the aggregate fair values of our borrowings were $40.0 billion and $33.7 billion, respectively, and the carrying values were $34.2 billion and $29.9 billion, respectively.

Derivative instruments

Derivative instruments	6 Months Ended
	Jun. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments	Derivative instruments The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes. Cash flow hedges We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales—primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods. As of both June 30, 2020 and December 31, 2019, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.0 billion. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings. To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings. The notional amounts and interest rates of our cross-currency swaps as of June 30, 2020, were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 1.25% 2022 euro Notes € 1,250 1.3 % $ 1,388 3.2 % 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 % In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI i n the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the six months ended June 30, 2020, and amounts expected to be recognized during the subsequent 12 months are not material. The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Three months ended Six months ended Derivatives in cash flow hedging relationships 2020 2019 2020 2019 Foreign currency contracts $ (101) $ (16) $ 138 $ 69 Cross-currency swap contracts 71 (80) (330) (135) Total unrealized losses $ (30) $ (96) $ (192) $ (66) Fair value hedges To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of June 30, 2020 and December 31, 2019, we had interest rate swap contracts with aggregate notional amounts of $7.4 billion and $9.6 billion, respectively, that hedge certain portions of our long-term debt issuances. Interest rate swaps with an aggregate notional value of $2.2 billion were terminated during the six months ended June 30, 2020, in connection with the redemption of certain of our notes. The terminations of these interest rate swaps resulted in a gain of $17 million, recognized in Interest expense, net, in the Condensed Consolidated Statements of Income. Additionally, we terminated $5.2 billion aggregate notional amount of interest rate swaps, which resulted in the receipt of $576 million from the counterparties that was included in Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2020. This amount will be recognized as a reduction in Interest expense, net, in the Condensed Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the terminations of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 9, Financing arrangements, for information on our interest rate swaps. For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt. The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) Condensed Consolidated Balance Sheets locations June 30, 2020 December 31, 2019 June 30, 2020 December 31, 2019 Current portion of long-term debt $ 89 $ 903 $ 89 $ 4 Long-term debt $ 7,816 $ 8,814 $ 589 $ 292 ____________ (1) Current portion of long-term debt includes $89 million of carrying value with discontinued hedging relationships as of June 30, 2020. Long-term debt includes $569 million and $136 million of carrying value with discontinued hedging relationships as of June 30, 2020 and December 31, 2019, respectively. (2) Current portion of long-term debt includes $89 million of hedging adjustments on discontinued hedging relationships as of June 30, 2020. Long-term debt includes $469 million and $36 million of hedging adjustments on discontinued hedging relationships as of June 30, 2020 and December 31, 2019, respectively. Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Three months ended June 30, 2020 Six months ended June 30, 2020 Product sales Interest and other income, net Interest (expense), net Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,908 $ 3 $ (296) $ 11,802 $ 14 $ (642) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 68 $ — $ — $ 117 $ — $ — Cross-currency swap contracts $ — $ 51 $ — $ — $ (82) $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (30) $ — $ — $ 180 Derivatives designated as hedging instruments $ — $ — $ 53 $ — $ — $ (137) Three months ended June 30, 2019 Six months ended June 30, 2019 Product sales Interest and other income, net Interest (expense), net Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,574 $ 218 $ (332) $ 10,860 $ 403 $ (675) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 22 $ — $ — $ 36 $ — $ — Cross-currency swap contracts $ — $ 14 $ — $ — $ (28) $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (218) $ — $ — $ (348) Derivatives designated as hedging instruments $ — $ — $ 218 $ — $ — $ 351 __________ (1) (Losses) gains on hedged items do not completely offset gains (losses) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period. No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of June 30, 2020, we expected to reclassify $95 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. Derivatives not designated as hedges To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of June 30, 2020 and December 31, 2019, the total notional amounts of these foreign currency forward contracts were $1.3 billion and $1.2 billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and six months ended June 30, 2020 and 2019. The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities June 30, 2020 Condensed Consolidated Fair values Condensed Consolidated Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 236 Accrued liabilities/ Other noncurrent liabilities $ 26 Cross-currency swap contracts Other current assets/ Other assets 27 Accrued liabilities/ Other noncurrent liabilities 604 Interest rate swap contracts Other current assets/ Other assets 121 Accrued liabilities/ Other noncurrent liabilities 2 Total derivatives designated as hedging instruments 384 632 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets — Accrued liabilities — Total derivatives not designated as hedging instruments — — Total derivatives $ 384 $ 632 Derivative assets Derivative liabilities December 31, 2019 Condensed Consolidated Fair values Condensed Consolidated Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 223 Accrued liabilities/ Other noncurrent liabilities $ 31 Cross-currency swap contracts Other current assets/ Other assets 66 Accrued liabilities/ Other noncurrent liabilities 315 Interest rate swap contracts Other current assets/ Other assets 259 Accrued liabilities/ Other noncurrent liabilities — Total derivatives designated as hedging instruments 548 346 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 549 $ 346 Our derivative contracts that were in liability positions as of June 30, 2020, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then-current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur. The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash provided by (used in) financing activities.

Contingencies and commitments

Contingencies and commitments	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments	Contingencies and commitments Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2019, Part I, Item 1A. Risk Factors— Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2020. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019; or in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2020, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019; or in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2020, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Abbreviated New Drug Application (ANDA) Patent Litigation KYPROLIS ® (carfilzomib) ANDA Patent Litigation Onyx Therapeutics, Inc. v. Cipla Limited, et al . On May 8, 2020, consistent with its May 4, 2020 decision and order, the U.S. District Court for the District of Delaware (the Delaware District Court) entered final judgment in favor of Onyx Therapeutics, Inc. (Onyx, a wholly-owned subsidiary of Amgen) and against Cipla Limited and Cipla USA, Inc. (collectively, Cipla) on infringement, validity and enforceability of claims 23 and 24 of U.S. Patent No. 7,417,042; claim 1 of U.S. Patent No. 8,207,125; and claim 31 of U.S. Patent No. 7,737,112 (the ’112 Patent). The Delaware District Court entered judgment in favor of Cipla and against Onyx on Cipla’s counterclaim for invalidity of claim 32 of the ’112 Patent and ordered that the effective date of any final approval by the U.S. Food and Drug Administration (FDA) of Cipla’s ANDA must be after expiration of the three asserted patents and any regulatory exclusivity to which Onyx may become entitled. The final judgment includes an injunction prohibiting Cipla from making, using, offering to sell, selling or importing into the United States Cipla’s carfilzomib product during the term of the three asserted patents. On May 29, 2020, Cipla filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). Otezla ® (apremilast) ANDA Patent Litigation Amgen Inc. v. Sandoz Inc., et al. On May 28, 2020, based on a joint request by Amgen and Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure), the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure’s apremilast product during the term of U.S. Patent Nos. 7,427,638 (the ’638 Patent); 7,893,101 (the ’101 Patent); 9,872,854 (the ’854 Patent); and 10,092,541 (the ’541 Patent) unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz Inc. (Sandoz) with respect to U.S. Patent Nos. 8,802,717; 7,208,516; and the ’854 Patent, leaving U.S. Patent Nos. 6,962,940; 7,659,302; 8,455,536; 9,018,243; and 9,724,330; the ’638 Patent; the ’101 Patent; and the ’541 Patent asserted by Amgen against Sandoz in the litigation. Sensipar ® (cinacalcet) ANDA Patent Litigation Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) Consolidated Case On July 9, 2020, the Federal Circuit Court granted a motion filed by Watson Laboratories, Inc. and Actavis Pharma, Inc. (collectively, Watson) and Amgen to dismiss Amgen’s appeals of the Delaware District Court’s judgment of noninfringement as to Watson and denial of the joint motion for indicative ruling. A hearing on the request by Piramal Healthcare UK Limited to recover damages for being enjoined during the pendency of Amgen’s appeal will be held by the Delaware District Court during the week of December 14, 2020. No trial date has been set for the patent infringement and validity issues to be tried in the remanded case against Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC. ENBREL (etanercept) Patent Litigation Immunex Corporation, et al. v. Sandoz Inc., et al. On July 1, 2020, the Federal Circuit Court affirmed the judgment of the New Jersey District Court upholding the validity of U.S. Patent Nos. 8,063,182 and 8,163,522. Repatha ® (evolocumab) Patent Litigation Patent Disputes in the International Region As previously disclosed, we are involved in and expect future involvement in additional disputes regarding our proprotein convertase subtilisin/kexin type 9 (PCSK9) patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in the United Kingdom, Germany, France, the Netherlands, Italy, Spain and Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen’s Japanese patents that were previously held infringed by PRALUENT ® and valid over challenges filed by Sanofi K.K. NEUPOGEN ® (filgrastim)/Neulasta ® (pegfilgrastim) Patent Litigation Fresenius Patent Trial and Appeal Board (PTAB) Challenge On June 23, 2020, the PTAB of the U.S. Patent and Trademark Office terminated two proceedings filed by Fresenius Kabi USA, LLC and Fresenius Kabi SwissBioSim GmbH (collectively, Fresenius) challenging the patentability of Amgen’s U.S. Patent Nos. 9,643,997 and 9,856,287 due to a settlement between Amgen and Fresenius. Litigation relating to our Biosimilar Products KANJINTI ® (trastuzumab-anns) Patent Litigation Genentech, Inc. v. Amgen Inc. On July 7, 2020, pursuant to a settlement and license agreement, Amgen and Genentech, Inc. stipulated to dismissal of the lawsuit. On July 9, 2020, the Delaware District Court closed the matter. MVASI ® (bevacizumab-awwb) Patent Litigation Genentech, Inc. and City of Hope v. Amgen Inc. On July 7, 2020, pursuant to a settlement and license agreement, Genentech, Inc. and City of Hope (collectively, Genentech) and Amgen stipulated to dismissal of the lawsuit. On July 9, 2020, the Delaware District Court closed the matter. Genentech, Inc. and City of Hope v. Immunex Rhode Island Corp. and Amgen Inc. On July 6, 2020, the Federal Circuit Court affirmed the Delaware District Court’s denial of Genentech’s request for injunction. On July 7, 2020, pursuant to a settlement and license agreement, the parties stipulated to dismissal of the lawsuit. On July 9, 2020, the Delaware District Court closed the matter. Breach of Contract Action Cipla Ltd. et al. v. Amgen Inc. On July 16, 2020, Amgen and Cipla filed a stipulation of dismissal. On July 21, 2020, the Delaware District Court issued an order dismissing all pending claims between Amgen and Cipla. Novartis Pharma AG v. Amgen Inc. On June 9, 2020, the U.S. District Court for the Southern District of New York (the New York Southern District Court) entered an order granting Novartis Pharma AG’s (Novartis) motion for judgment on the pleadings as to count II of Novartis’s amended complaint and denying Amgen’s motions for judgment on the pleadings as to counts I, II and IV of Novartis’s amended complaint. On June 23, 2020, Amgen filed a motion for clarification and/or reconsideration of the New York Southern District Court’s June 9, 2020 order. On July 7, and July 14, 2020, respectively, Novartis and Amgen each filed its response. No trial date has been set. Antitrust Class Action Sensipar ® Antitrust Class Actions On July 22, 2020, the U.S. Magistrate Judge for the District of Delaware issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but recommended that leave be given to plaintiffs to amend their complaints. Humira ® Biosimilar Antitrust Class Actions On June 8, 2020, the U.S. District Court for the Northern District of Illinois (the Illinois Northern District Court) issued an order granting the motion by the defendants Amgen, along with AbbVie Inc. and AbbVie Biotechnology Ltd., Samsung Bioepis Co., Ltd., Sandoz and Fresenius Kabi USA LLC., to dismiss the consolidated class action complaint. On June 29, 2020, the plaintiffs in the antitrust class action lawsuit filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion and the plaintiffs have 30 days therefrom to file their notice of appeal.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Business	Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation	Basis of presentation The financial information for the three and six months ended June 30, 2020 and 2019, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2019, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2020.
Principles of consolidation	Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.7 billion and $8.4 billion as of June 30, 2020 and December 31, 2019, respectively.
Equity method investments	Equity method investments The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Condensed Consolidated Statements of Income.
Other recent accounting pronouncements	Recent accounting pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our condensed consolidated financial statements. In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022, as a result of reference rate reform. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.

Revenues (Tables)

Revenues (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue by product and by geographic area	Revenues were as follows (in millions): Three months ended June 30, 2020 2019 US ROW Total US ROW Total Enbrel ® (etanercept) $ 1,213 $ 33 $ 1,246 $ 1,315 $ 48 $ 1,363 Prolia ® (denosumab) 441 218 659 458 240 698 Neulasta ® (pegfilgrastim) 520 73 593 719 105 824 Otezla ® (apremilast) 464 97 561 — — — XGEVA ® (denosumab) 318 117 435 379 120 499 Aranesp ® (darbepoetin alfa) 156 231 387 192 244 436 KYPROLIS ® (carfilzomib) 167 86 253 166 101 267 Repatha ® (evolocumab) 115 85 200 91 61 152 Other products 1,034 540 1,574 822 513 1,335 Total product sales (1) $ 4,428 $ 1,480 5,908 $ 4,142 $ 1,432 5,574 Other revenues 298 297 Total revenues $ 6,206 $ 5,871 Six months ended June 30, 2020 2019 US ROW Total US ROW Total ENBREL $ 2,330 $ 69 $ 2,399 $ 2,421 $ 93 $ 2,514 Prolia ® 863 450 1,313 848 442 1,290 Neulasta ® 1,054 148 1,202 1,612 233 1,845 Otezla ® 841 199 1,040 — — — XGEVA ® 673 243 916 735 235 970 Aranesp ® 331 478 809 374 476 850 KYPROLIS ® 354 179 533 320 192 512 Repatha ® 239 190 429 174 119 293 Other products 2,022 1,139 3,161 1,649 937 2,586 Total product sales (1) $ 8,707 $ 3,095 11,802 $ 8,133 $ 2,727 10,860 Other revenues 565 568 Total revenues $ 12,367 $ 11,428 ____________

Earnings per share (Tables)

Earnings per share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Computation for basic and diluted earnings per share	The computations for basic and diluted EPS were as follows (in millions, except per-share data): Three months ended Six months ended 2020 2019 2020 2019 Income (Numerator): Net income for basic and diluted EPS $ 1,803 $ 2,179 $ 3,628 $ 4,171 Shares (Denominator): Weighted-average shares for basic EPS 588 607 589 615 Effect of dilutive securities 4 3 4 3 Weighted-average shares for diluted EPS 592 610 593 618 Basic EPS $ 3.07 $ 3.59 $ 6.16 $ 6.78 Diluted EPS $ 3.05 $ 3.57 $ 6.12 $ 6.75

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of June 30, 2020 Amortized Gross Gross Fair U.S. Treasury notes $ 172 $ 3 $ — $ 175 U.S. Treasury bills 3,399 — — 3,399 Corporate debt securities: Financial — — — — Industrial 3 — (1) 2 Other — — — — Residential-mortgage-backed securities — — — — Money market mutual funds 7,158 — — 7,158 Other short-term interest-bearing securities — — — — Total interest-bearing securities $ 10,732 $ 3 $ (1) $ 10,734 Types of securities as of December 31, 2019 Amortized Gross Gross Fair U.S. Treasury notes $ 359 $ 1 $ — $ 360 U.S. Treasury bills — — — — Corporate debt securities: Financial 1,108 13 — 1,121 Industrial 824 10 — 834 Other 195 3 — 198 Residential-mortgage-backed securities 181 1 — 182 Money market mutual funds 5,250 — — 5,250 Other short-term interest-bearing securities 289 — — 289 Total interest-bearing securities $ 8,206 $ 28 $ — $ 8,234
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions): Condensed Consolidated Balance Sheets locations June 30, 2020 December 31, 2019 Cash and cash equivalents $ 8,458 $ 5,360 Marketable securities 2,276 2,874 Total interest-bearing securities $ 10,734 $ 8,234
Fair values of available-for-sale interest-bearing security investments by contractual maturity	The fair values of interest-bearing securities by contractual maturity, except for residential-mortgage-backed securities that do not have a single maturity date, were as follows (in millions): Contractual maturities June 30, 2020 December 31, 2019 Maturing in one year or less $ 10,681 $ 5,629 Maturing after one year through three years 53 2,304 Maturing after three years through five years — 119 Residential-mortgage-backed securities — 182 Total interest-bearing securities $ 10,734 $ 8,234

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories consisted of the following (in millions): June 30, 2020 December 31, 2019 Raw materials $ 463 $ 358 Work in process 2,376 2,227 Finished goods 1,001 999 Total inventories $ 3,840 $ 3,584

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The change in the carrying amount of goodwill was as follows (in millions): Six months ended Beginning balance $ 14,703 Currency translation adjustment (25) Ending balance $ 14,678
Schedule of identifiable intangible assets	Other intangible assets consisted of the following (in millions): June 30, 2020 December 31, 2019 Gross Accumulated Other intangible Gross Accumulated Other intangible Finite-lived intangible assets: Developed-product-technology rights $ 25,559 $ (9,436) $ 16,123 $ 25,575 $ (8,322) $ 17,253 Licensing rights 3,746 (2,602) 1,144 3,761 (2,398) 1,363 Marketing-related rights 1,371 (1,003) 368 1,382 (965) 417 Research and development technology rights 1,279 (996) 283 1,273 (947) 326 Total finite-lived intangible assets 31,955 (14,037) 17,918 31,991 (12,632) 19,359 Indefinite-lived intangible assets: In-process research and development 30 — 30 54 — 54 Total other intangible assets $ 31,985 $ (14,037) $ 17,948 $ 32,045 $ (12,632) $ 19,413

Financing arrangements (Tables)

Financing arrangements (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of borrowings	Our borrowings consisted of the following (in millions): June 30, 2020 December 31, 2019 4.50% notes due 2020 (4.50% 2020 Notes) $ — $ 300 2.125% notes due 2020 (2.125% 2020 Notes) — 750 Floating Rate Notes due 2020 — 300 2.20% notes due 2020 (2.20% 2020 Notes) — 700 3.45% notes due 2020 (3.45% 2020 Notes) — 900 4.10% notes due 2021 (4.10% 2021 Notes) — 1,000 1.85% notes due 2021 (1.85% 2021 Notes) — 750 3.875% notes due 2021 (3.875% 2021 Notes) 1,450 1,750 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) 1,404 1,402 2.70% notes due 2022 (2.70% 2022 Notes) 500 500 2.65% notes due 2022 (2.65% 2022 Notes) 1,500 1,500 3.625% notes due 2022 (3.625% 2022 Notes) 750 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 739 725 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 1.90% notes due 2025 (1.90% 2025 Notes) 500 — 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 843 841 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 589 630 2.20% notes due 2027 (2.20% 2027 Notes) 1,750 — 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 868 928 2.45% notes due 2030 (2.45% 2030 Notes) 1,250 — 2.30% notes due 2031 (2.30% 2031 Notes) 1,250 — 6.375% notes due 2037 (6.375% 2037 Notes) 552 552 6.90% notes due 2038 (6.90% 2038 Notes) 291 291 6.40% notes due 2039 (6.40% 2039 Notes) 466 466 3.15% notes due 2040 (3.15% 2040 Notes) 2,000 — 5.75% notes due 2040 (5.75% 2040 Notes) 412 412 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 974 974 5.65% notes due 2042 (5.65% 2042 Notes) 487 487 5.375% notes due 2043 (5.375% 2043 Notes) 261 261 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 3.375% notes due 2050 (3.375% 2050 Notes) 2,250 — 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (849) (868) Fair value adjustments 678 296 Other 3 — Total carrying value of debt 34,224 29,903 Less current portion (91) (2,953) Total long-term debt $ 34,133 $ 26,950
Schedule of interest rate swaps	The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions): June 30, 2020 December 31, 2019 Notes Notional amounts Effective interest rates Notional amounts Effective interest rates 3.45% 2020 Notes $ — LIBOR + 1.1% $ 900 LIBOR + 1.1% 4.10% 2021 Notes — LIBOR + 1.7% 1,000 LIBOR + 1.7% 3.875% 2021 Notes 1,450 LIBOR + 2.0% 1,750 LIBOR + 2.0% 3.625% 2022 Notes 750 LIBOR + 2.7% 750 LIBOR + 1.6% 3.625% 2024 Notes 1,400 LIBOR + 3.2% 1,400 LIBOR + 1.4% 3.125% 2025 Notes 1,000 LIBOR + 1.8% 1,000 LIBOR + 0.9% 2.60% 2026 Notes 1,250 LIBOR + 1.8% 1,250 LIBOR + 0.3% 4.663% 2051 Notes (1) 1,500 LIBOR + 2.6% 1,500 LIBOR + 0.0% Total notional amounts $ 7,350 $ 9,550 ____________ (1) Excludes an additional 1.5% of interest for the difference between the coupon rate paid to note holders and the fixed rate received under the interest rate swap contracts.

Stockholders' equity (Tables)

Stockholders' equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Summary of activity under our stock repurchase program	Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): 2020 2019 Shares Dollars Shares * Dollars First quarter 4.3 $ 933 15.9 $ 3,031 Second quarter 2.6 591 13.1 2,349 Total stock repurchases 6.9 $ 1,524 28.9 $ 5,380
Components of accumulated other comprehensive income	The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions): Foreign Cash flow Available-for-sale Other AOCI Balance as of December 31, 2019 $ (718) $ 175 $ 22 $ (7) $ (528) Foreign currency translation adjustments (52) — — — (52) Unrealized (losses) gains — (162) 8 — (154) Reclassification adjustments to income — 84 (33) — 51 Other — — — (2) (2) Income taxes — 17 6 — 23 Balance as of March 31, 2020 (770) 114 3 (9) (662) Foreign currency translation adjustments (3) — — — (3) Unrealized losses — (30) (2) — (32) Reclassification adjustments to income — (119) — — (119) Other — — — — — Income taxes — 33 — — 33 Balance as of June 30, 2020 $ (773) $ (2) $ 1 $ (9) $ (783)
Reclassifications out of accumulated other comprehensive income	Reclassifications out of AOCI and into earnings were as follows (in millions): Three months ended June 30, Components of AOCI 2020 2019 Condensed Consolidated Cash flow hedges: Foreign currency contract gains $ 68 $ 22 Product sales Cross-currency swap contract gains 51 14 Interest and other income, net 119 36 Income before income taxes (26) (8) Provision for income taxes $ 93 $ 28 Net income Available-for-sale securities: Net realized losses $ — $ (2) Interest and other income, net — — Provision for income taxes $ — $ (2) Net income Six months ended June 30, Components of AOCI 2020 2019 Condensed Consolidated Cash flow hedges: Foreign currency contract gains $ 117 $ 36 Product sales Cross-currency swap contract losses (82) (28) Interest and other income, net 35 8 Income before income taxes (8) (2) Provision for income taxes $ 27 $ 6 Net income Available-for-sale securities: Net realized gains (losses) $ 33 $ (6) Interest and other income, net (7) — Provision for income taxes $ 26 $ (6) Net income

Fair value measurement (Tables)

Fair value measurement (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis	The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Quoted prices in Significant Significant Fair value measurement as of June 30, 2020, using: Total Assets: Available-for-sale securities: U.S. Treasury notes $ 175 $ — $ — $ 175 U.S. Treasury bills 3,399 — — 3,399 Corporate debt securities: Financial — — — — Industrial — 2 — 2 Other — — — — Residential-mortgage-backed securities — — — — Money market mutual funds 7,158 — — 7,158 Other short-term interest-bearing securities — — — — Equity securities 297 — — 297 Derivatives: Foreign currency contracts — 236 — 236 Cross-currency swap contracts — 27 — 27 Interest rate swap contracts — 121 — 121 Total assets $ 11,029 $ 386 $ — $ 11,415 Liabilities: Derivatives: Foreign currency contracts $ — $ 26 $ — $ 26 Cross-currency swap contracts — 604 — 604 Interest rate swap contracts — 2 — 2 Contingent consideration obligations — — 55 55 Total liabilities $ — $ 632 $ 55 $ 687 Quoted prices in Significant Significant Fair value measurement as of December 31, 2019, using: Total Assets: Available-for-sale securities: U.S. Treasury notes $ 360 $ — $ — $ 360 U.S. Treasury bills — — — — Corporate debt securities: Financial — 1,121 — 1,121 Industrial — 834 — 834 Other — 198 — 198 Residential-mortgage-backed securities — 182 — 182 Money market mutual funds 5,250 — — 5,250 Other short-term interest-bearing securities — 289 — 289 Equity securities 303 — — 303 Derivatives: Foreign currency contracts — 224 — 224 Cross-currency swap contracts — 66 — 66 Interest rate swap contracts — 259 — 259 Total assets $ 5,913 $ 3,173 $ — $ 9,086 Liabilities: Derivatives: Foreign currency contracts $ — $ 31 $ — $ 31 Cross-currency swap contracts — 315 — 315 Interest rate swap contracts — — — — Contingent consideration obligations — — 61 61 Total liabilities $ — $ 346 $ 61 $ 407

Derivative instruments (Tables)

Derivative instruments (Tables)	6 Months Ended
	Jun. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of notional amounts and interest rates for cross-currency swaps	The notional amounts and interest rates of our cross-currency swaps as of June 30, 2020, were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 1.25% 2022 euro Notes € 1,250 1.3 % $ 1,388 3.2 % 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 %
Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges	The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Three months ended Six months ended Derivatives in cash flow hedging relationships 2020 2019 2020 2019 Foreign currency contracts $ (101) $ (16) $ 138 $ 69 Cross-currency swap contracts 71 (80) (330) (135) Total unrealized losses $ (30) $ (96) $ (192) $ (66)
Derivatives in fair value hedging relationships	The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) Condensed Consolidated Balance Sheets locations June 30, 2020 December 31, 2019 June 30, 2020 December 31, 2019 Current portion of long-term debt $ 89 $ 903 $ 89 $ 4 Long-term debt $ 7,816 $ 8,814 $ 589 $ 292 ____________ (1) Current portion of long-term debt includes $89 million of carrying value with discontinued hedging relationships as of June 30, 2020. Long-term debt includes $569 million and $136 million of carrying value with discontinued hedging relationships as of June 30, 2020 and December 31, 2019, respectively. (2) Current portion of long-term debt includes $89 million of hedging adjustments on discontinued hedging relationships as of June 30, 2020. Long-term debt includes $469 million and $36 million of hedging adjustments on discontinued hedging relationships as of June 30, 2020 and December 31, 2019, respectively.
Summary of amounts of income and expense line items	The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Three months ended June 30, 2020 Six months ended June 30, 2020 Product sales Interest and other income, net Interest (expense), net Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,908 $ 3 $ (296) $ 11,802 $ 14 $ (642) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 68 $ — $ — $ 117 $ — $ — Cross-currency swap contracts $ — $ 51 $ — $ — $ (82) $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (30) $ — $ — $ 180 Derivatives designated as hedging instruments $ — $ — $ 53 $ — $ — $ (137) Three months ended June 30, 2019 Six months ended June 30, 2019 Product sales Interest and other income, net Interest (expense), net Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,574 $ 218 $ (332) $ 10,860 $ 403 $ (675) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 22 $ — $ — $ 36 $ — $ — Cross-currency swap contracts $ — $ 14 $ — $ — $ (28) $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (218) $ — $ — $ (348) Derivatives designated as hedging instruments $ — $ — $ 218 $ — $ — $ 351 __________ (1) (Losses) gains on hedged items do not completely offset gains (losses) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges where the corresponding hedged item was paid down in the period.
Fair values of derivatives included in the Condensed Consolidated Balance Sheets	The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities June 30, 2020 Condensed Consolidated Fair values Condensed Consolidated Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 236 Accrued liabilities/ Other noncurrent liabilities $ 26 Cross-currency swap contracts Other current assets/ Other assets 27 Accrued liabilities/ Other noncurrent liabilities 604 Interest rate swap contracts Other current assets/ Other assets 121 Accrued liabilities/ Other noncurrent liabilities 2 Total derivatives designated as hedging instruments 384 632 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets — Accrued liabilities — Total derivatives not designated as hedging instruments — — Total derivatives $ 384 $ 632 Derivative assets Derivative liabilities December 31, 2019 Condensed Consolidated Fair values Condensed Consolidated Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 223 Accrued liabilities/ Other noncurrent liabilities $ 31 Cross-currency swap contracts Other current assets/ Other assets 66 Accrued liabilities/ Other noncurrent liabilities 315 Interest rate swap contracts Other current assets/ Other assets 259 Accrued liabilities/ Other noncurrent liabilities — Total derivatives designated as hedging instruments 548 346 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 549 $ 346

Summary of significant accoun_3

Summary of significant accounting policies (Details) $ in Billions	6 Months Ended
	Jun. 30, 2020USD ($)segment	Dec. 31, 2019USD ($)
Accounting Policies [Abstract]
Number of operating segments | segment	1
Accumulated depreciation and amortization on property, plant and equipment | $	$ 8.7	$ 8.4

Revenues (Details)

Revenues (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)segment	Jun. 30, 2019USD ($)
Revenue from Contract with Customer [Abstract]
Number of operating segments | segment			1
Revenue from External Customer [Line Items]
Total revenues	$ 6,206	$ 5,871	$ 12,367	$ 11,428
Product sales [Member]
Revenue from External Customer [Line Items]
Total product sales	5,908	5,574	11,802	10,860
Product sales [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	4,428	4,142	8,707	8,133
Product sales [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	1,480	1,432	3,095	2,727
Enbrel® (etanercept) [Member]
Revenue from External Customer [Line Items]
Total product sales	1,246	1,363	2,399	2,514
Enbrel® (etanercept) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	1,213	1,315	2,330	2,421
Enbrel® (etanercept) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	33	48	69	93
Prolia® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	659	698	1,313	1,290
Prolia® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	441	458	863	848
Prolia® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	218	240	450	442
Neulasta® (pegfilgrastim) [Member]
Revenue from External Customer [Line Items]
Total product sales	593	824	1,202	1,845
Neulasta® (pegfilgrastim) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	520	719	1,054	1,612
Neulasta® (pegfilgrastim) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	73	105	148	233
Otezla (apremilast) [Member]
Revenue from External Customer [Line Items]
Total product sales	561	0	1,040	0
Otezla (apremilast) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	464	0	841	0
Otezla (apremilast) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	97	0	199	0
XGEVA® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	435	499	916	970
XGEVA® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	318	379	673	735
XGEVA® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	117	120	243	235
Aranesp® (darbepoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total product sales	387	436	809	850
Aranesp® (darbepoetin alfa) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	156	192	331	374
Aranesp® (darbepoetin alfa) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	231	244	478	476
KYPROLIS® (carfilzomib) [Member]
Revenue from External Customer [Line Items]
Total product sales	253	267	533	512
KYPROLIS® (carfilzomib) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	167	166	354	320
KYPROLIS® (carfilzomib) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	86	101	179	192
Repatha (evolocumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	200	152	429	293
Repatha (evolocumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	115	91	239	174
Repatha (evolocumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	85	61	190	119
Other products [Member]
Revenue from External Customer [Line Items]
Total product sales	1,574	1,335	3,161	2,586
Other products [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	1,034	822	2,022	1,649
Other products [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	540	513	1,139	937
Other revenues [Member]
Revenue from External Customer [Line Items]
Total revenues	$ 298	$ 297	$ 565	$ 568

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Effective income tax rate	11.20%	15.00%	10.40%	14.50%
Increase in unrecognized tax benefits resulting from tax positions taken during the current period	$ 55		$ 105

Earnings per share (Details)

Earnings per share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Income (Numerator):
Net income for basic and diluted EPS	$ 1,803	$ 1,825	$ 2,179	$ 1,992	$ 3,628	$ 4,171
Shares (Denominator):
Weighted-average shares for basic EPS (in shares)	588		607		589	615
Effect of dilutive securities (in shares)	4		3		4	3
Weighted-average shares for diluted EPS (in shares)	592		610		593	618
Basic EPS (in usd per share)	$ 3.07		$ 3.59		$ 6.16	$ 6.78
Diluted EPS (in usd per share)	$ 3.05		$ 3.57		$ 6.12	$ 6.75

Collaborations (Details)

Collaborations (Details) - Collaborative arrangement with BeiGene, Ltd. [Member] - USD ($)	Jan. 02, 2020	Jun. 30, 2020	Jun. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Global research and development costs (up to)	$ 1,250,000,000
Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recovery of Direct Costs		$ 55,000,000	$ 112,000,000

Investments (Details)

Investments (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Amortized cost	$ 10,732,000,000	$ 8,206,000,000
Gross unrealized gains	3,000,000	28,000,000
Gross unrealized losses	(1,000,000)	0
Fair values	10,734,000,000	8,234,000,000
U.S. Treasury notes [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	172,000,000	359,000,000
Gross unrealized gains	3,000,000	1,000,000
Gross unrealized losses	0	0
Fair values	175,000,000	360,000,000
U.S. Treasury bills [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	3,399,000,000	0
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	3,399,000,000	0
Corporate debt securities - Financial [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	0	1,108,000,000
Gross unrealized gains	0	13,000,000
Gross unrealized losses	0	0
Fair values	0	1,121,000,000
Corporate debt securities - Industrial [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	3,000,000	824,000,000
Gross unrealized gains	0	10,000,000
Gross unrealized losses	(1,000,000)	0
Fair values	2,000,000	834,000,000
Corporate debt securities - Other [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	0	195,000,000
Gross unrealized gains	0	3,000,000
Gross unrealized losses	0	0
Fair values	0	198,000,000
Residential mortgage-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	0	181,000,000
Gross unrealized gains	0	1,000,000
Gross unrealized losses	0	0
Fair values	0	182,000,000
Money market mutual funds [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	7,158,000,000	5,250,000,000
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	7,158,000,000	5,250,000,000
Other short-term interest-bearing securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	0	289,000,000
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	$ 0	$ 289,000,000

Investments (Fair Values by Cla

Investments (Fair Values by Classification) (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	$ 9,145	$ 6,037
Marketable securities	2,276	2,874
Total interest-bearing securities	10,734	8,234
Available-for-sale investments [Member]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	8,458	5,360
Marketable securities	2,276	2,874
Total interest-bearing securities	$ 10,734	$ 8,234

Investments (Available-for-sale

Investments (Available-for-sale Investments) (Details Textual) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Cash and cash equivalents	$ 687		$ 677
Total realized gains	37	$ 2
Total realized losses	$ 4	$ 8

Investments (Fair Values by Con

Investments (Fair Values by Contractual Maturity) (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Maturing in one year or less	$ 10,681	$ 5,629
Maturing after one year through three years	53	2,304
Maturing after three years through five years	0	119
Residential-mortgage-backed securities	0	182
Total interest-bearing securities	$ 10,734	$ 8,234

Investments (Equity Securities)

Investments (Equity Securities) (Details Textual) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Equity securities	$ 297		$ 303
Equity securities without readily determinable fair value	183		$ 176
Debt Securities, Available-for-sale, Realized Gain	37	$ 2
Debt Securities, Available-for-sale, Realized Loss	$ 4	$ 8

Investments Investments (Limite

Investments Investments (Limited Partnership Investments) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Jul. 15, 2020	Jan. 02, 2020	Dec. 31, 2019
Limited Partnership [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Net Investment Income [Line Items]
Investments	$ 311	$ 311			$ 320
BeiGene [Member]
Net Investment Income [Line Items]
Carrying value of equity method investment	$ 2,500	$ 2,500
Equity Method Investment, Aggregate Cost				$ 2,800
Ownership percentage	20.40%	20.40%		20.50%
Equity Method Investments,Quoted Market Price	$ 3,000	$ 3,000		$ 2,600
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity				$ 2,400
Equity method investment, change in carrying value	111	111
Income (Loss) from Equity Method Investments	75	75
Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity	$ 36	$ 36
BeiGene [Member] | Subsequent Event [Member]
Net Investment Income [Line Items]
Equity Method Investment, Aggregate Cost			$ 421
Minimum [Member] | BeiGene [Member]
Net Investment Income [Line Items]
Finite-Lived Intangible Asset, Useful Life		8 years
Maximum [Member] | BeiGene [Member]
Net Investment Income [Line Items]
Finite-Lived Intangible Asset, Useful Life		15 years

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 463	$ 358
Work in process	2,376	2,227
Finished goods	1,001	999
Total inventories	$ 3,840	$ 3,584

Goodwill and other intangible_3

Goodwill and other intangible assets (Goodwill Roll Forward) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2020USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 14,703
Currency translation adjustment	(25)
Ending balance	$ 14,678

Goodwill and other intangible_4

Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	$ 31,955	$ 31,991
Accumulated amortization	(14,037)	(12,632)
Other intangible assets, net	17,918	19,359
Gross carrying amount	31,985	32,045
Accumulated amortization	(14,037)	(12,632)
Intangible assets, net	17,948	19,413
In-process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	30	54
Developed-Product-Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	25,559	25,575
Accumulated amortization	(9,436)	(8,322)
Other intangible assets, net	16,123	17,253
Licensing Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	3,746	3,761
Accumulated amortization	(2,602)	(2,398)
Other intangible assets, net	1,144	1,363
Marketing-Related Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	1,371	1,382
Accumulated amortization	(1,003)	(965)
Other intangible assets, net	368	417
Research and Development Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	1,279	1,273
Accumulated amortization	(996)	(947)
Other intangible assets, net	$ 283	$ 326

Goodwill and other intangible_5

Goodwill and other intangible assets (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization charges associated with finite-lived intangible assets	$ 713	$ 315	$ 1,400	$ 630
Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2019	1,400		1,400
Total estimated amortization of finite-lived intangible assets for 2020	2,600		2,600
Total estimated amortization of finite-lived intangible assets for 2021	2,500		2,500
Total estimated amortization of finite-lived intangible assets for 2022	2,400		2,400
Total estimated amortization of finite-lived intangible assets for 2023	2,400		2,400
Total estimated amortization of finite-lived intangible assets for 2024	$ 2,200		$ 2,200

Financing arrangements (Princip

Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2020EUR (€)	Jun. 30, 2020CHF (SFr)	Jun. 30, 2020GBP (£)	Jun. 30, 2020USD ($)	May 31, 2020USD ($)	Mar. 31, 2020	Feb. 29, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Unamortized bond discounts, premiums and issuance costs, net				$ (849)				$ (868)
Fair value adjustments				678				296
Other				3				0
Total carrying value of debt				34,224				29,903
Less current portion				(91)				(2,953)
Total long-term debt				$ 34,133				26,950
Notes [Member]
Debt Instrument [Line Items]
Face amount					$ 4,000		$ 5,000
Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.50%	4.50%	4.50%	4.50%			4.50%
Long-term debt, gross								300
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.125%	2.125%	2.125%	2.125%			2.125%
Long-term debt, gross				$ 0				750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | Floating Rate Notes Due 2020 [Member]
Debt Instrument [Line Items]
Long-term debt, gross				$ 0				300
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%			2.20%
Long-term debt, gross				$ 0				700
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.45%	3.45%	3.45%	3.45%			3.45%
Long-term debt, gross								900
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.10%	4.10%	4.10%	4.10%			4.10%
Long-term debt, gross								1,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.85%	1.85%	1.85%	1.85%			1.85%
Long-term debt, gross				$ 0				750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.875%	3.875%	3.875%	3.875%			3.875%
Long-term debt, gross				$ 1,450				1,750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.25%	1.25%	1.25%	1.25%
Long-term debt, gross				$ 1,404				1,402
Face amount | €	€ 1,250,000,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.70% notes due 2022 (2.70% 2022 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.70%	2.70%	2.70%	2.70%
Long-term debt, gross				$ 500				500
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.65% notes due 2022 (2.65% 2022 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.65%	2.65%	2.65%	2.65%
Long-term debt, gross				$ 1,500				1,500
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%		3.625%
Long-term debt, gross				$ 750				750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
Long-term debt, gross				$ 739				725
Face amount | SFr		SFr 700,000,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.25% notes due 2023 (2.25% 2023 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.25%	2.25%	2.25%	2.25%
Long-term debt, gross				$ 750				750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%		3.625%
Long-term debt, gross				$ 1,400				1,400
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.90%	1.90%	1.90%	1.90%			1.90%
Long-term debt, gross				$ 500
Face amount							$ 500
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%	3.125%	3.125%	3.125%		3.125%
Long-term debt, gross				$ 1,000				1,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.00%	2.00%	2.00%	2.00%
Long-term debt, gross				$ 843				841
Face amount | €	€ 750,000,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.60%	2.60%	2.60%	2.60%		2.60%
Long-term debt, gross				$ 1,250				1,250
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.50%	5.50%	5.50%	5.50%
Long-term debt, gross				$ 589				630
Face amount | £			£ 475,000,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.20% notes due 2027 (2.20% 2027 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%	2.20%		2.20%
Long-term debt, gross				$ 1,750
Face amount					$ 1,000		$ 750
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.20%	3.20%	3.20%	3.20%
Long-term debt, gross				$ 1,000				1,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.00%	4.00%	4.00%	4.00%
Long-term debt, gross				$ 868				928
Face amount | £			£ 700,000,000
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.45%	2.45%	2.45%	2.45%			2.45%
Long-term debt, gross				$ 1,250
Face amount							$ 1,250
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.30%	2.30%	2.30%	2.30%	2.30%
Long-term debt, gross				$ 1,250
Face amount					$ 1,250
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	6.375%	6.375%	6.375%	6.375%
Long-term debt, gross				$ 552				552
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	6.90%	6.90%	6.90%	6.90%
Long-term debt, gross				$ 291				291
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	6.40%	6.40%	6.40%	6.40%
Long-term debt, gross				$ 466				466
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.15%	3.15%	3.15%	3.15%	3.15%		3.15%
Long-term debt, gross				$ 2,000
Face amount					$ 750		$ 1,250
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.75%	5.75%	5.75%	5.75%
Long-term debt, gross				$ 412				412
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 4.95% notes due 2041 (4.95% 2041 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.95%	4.95%	4.95%	4.95%
Long-term debt, gross				$ 600				600
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.15%	5.15%	5.15%	5.15%
Long-term debt, gross				$ 974				974
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.65%	5.65%	5.65%	5.65%
Long-term debt, gross				$ 487				487
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.375%	5.375%	5.375%	5.375%
Long-term debt, gross				$ 261				261
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 4.40% notes due 2045 (4.40% 2045 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.40%	4.40%	4.40%	4.40%
Long-term debt, gross				$ 2,250				2,250
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.563%	4.563%	4.563%	4.563%
Long-term debt, gross				$ 1,415				1,415
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 3.375% notes due 2050 (3.375% 2050 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.375%	3.375%	3.375%	3.375%	3.375%		3.375%
Long-term debt, gross				$ 2,250
Face amount					$ 1,000		$ 1,250
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%	4.663%	4.663%	4.663%		4.663%
Long-term debt, gross				$ 3,541				3,541
Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event	101.00%
Notes [Member] | Other notes due 2097 [Member]
Debt Instrument [Line Items]
Long-term debt, gross				$ 100				$ 100

Financing arrangements (Details

Financing arrangements (Details Textual) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Feb. 29, 2020	Jun. 30, 2020	Jun. 30, 2019	May 31, 2020	Mar. 31, 2020
Debt Instrument [Line Items]
Repayments of Long-term Debt		$ 5,000	$ 3,650
Notes [Member]
Debt Instrument [Line Items]
Face amount	$ 5,000			$ 4,000
Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage		4.563%
Effective interest rate		6.30%
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage		4.663%			4.663%
Effective interest rate		5.60%
Notes [Member] | Interest Expense [Member]
Debt Instrument [Line Items]
MakeWholePayments	$ 50
Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.90%	1.90%
Face amount	$ 500
Notes [Member] | 2.20% notes due 2027 (2.20% 2027 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%	2.20%		2.20%
Face amount	$ 750			$ 1,000
Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.45%	2.45%
Face amount	$ 1,250
Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.15%	3.15%		3.15%
Face amount	$ 1,250			$ 750
Notes [Member] | 3.375% notes due 2050 (3.375% 2050 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.375%	3.375%		3.375%
Face amount	$ 1,250			$ 1,000
Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.45%	3.45%
Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.10%	4.10%
Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.85%	1.85%
Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.875%	3.875%
Repayments of Long-term Debt	$ 300
Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.50%	4.50%
Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage		2.30%		2.30%
Face amount				$ 1,250
Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.125%	2.125%
Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%	2.20%
Minimum [Member] | Debt Securities Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Period without Payment of Make Whole Amount		1 month
Maximum [Member] | Debt Securities Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Period without Payment of Make Whole Amount		6 months

Financing arrangements (Schedul

Financing arrangements (Schedule Interest Rate Swaps) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Rate difference in an interest rate swap relationship	1.50%
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Notional amounts	$ 7,350	$ 9,550
Notes Payable, Other Payables [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Debt Instrument [Line Items]
Notional amounts	$ 0	$ 900
Interest rate, stated percentage	3.45%
Notes Payable, Other Payables [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	1.10%	1.10%
Notes Payable, Other Payables [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Debt Instrument [Line Items]
Notional amounts	$ 0	$ 1,000
Interest rate, stated percentage	4.10%
Notes Payable, Other Payables [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	1.70%	1.70%
Notes Payable, Other Payables [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Debt Instrument [Line Items]
Notional amounts	$ 1,450	$ 1,750
Interest rate, stated percentage	3.875%
Notes Payable, Other Payables [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	2.00%	2.00%
Notes Payable, Other Payables [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Debt Instrument [Line Items]
Notional amounts	$ 750	$ 750
Interest rate, stated percentage	3.625%
Notes Payable, Other Payables [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	2.70%	1.60%
Notes Payable, Other Payables [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Debt Instrument [Line Items]
Notional amounts	$ 1,400	$ 1,400
Interest rate, stated percentage	3.625%
Notes Payable, Other Payables [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	3.20%	1.40%
Notes Payable, Other Payables [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]
Debt Instrument [Line Items]
Notional amounts	$ 1,000	$ 1,000
Interest rate, stated percentage	3.125%
Notes Payable, Other Payables [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	1.80%	0.90%
Notes Payable, Other Payables [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Notional amounts	$ 1,250	$ 1,250
Interest rate, stated percentage	2.60%
Notes Payable, Other Payables [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	1.80%	0.30%
Notes Payable, Other Payables [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Notional amounts	$ 1,500	$ 1,500
Interest rate, stated percentage	4.663%
Notes Payable, Other Payables [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	2.60%	0.00%

Financing arrangements (Interes

Financing arrangements (Interest Rate Swaps Textual) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	May 31, 2020	Feb. 29, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Net cash provided by operating activities		$ 4,976	$ 3,259
Repayments of Long-term Debt		$ 5,000	$ 3,650
4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Rate difference in an interest rate swap relationship		1.50%
Notes [Member]
Debt Instrument [Line Items]
Face amount				$ 4,000	$ 5,000
Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%
Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.60%	2.60%
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%	4.663%
Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%
Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%	3.125%
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]
Debt Instrument [Line Items]
Notional amounts		$ 7,400				$ 9,600
Value of derivative contracts terminated		2,200
Net cash provided by operating activities	$ 576	$ 576
$2.2 Billion Notional Value Interest Rate Swap [Member] | Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]
Debt Instrument [Line Items]
Value of derivative contracts terminated	2,200
$5.2 Billion Notional Value Interest Rate Swap, Original [Member] | Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]
Debt Instrument [Line Items]
Value of derivative contracts terminated	5,200
$5.2 Billion Notional Value Interest Rate Swap [Member] | Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]
Debt Instrument [Line Items]
Notional amounts	$ 5,200

Stockholders' equity (Share Rep

Stockholders' equity (Share Repurchase Program) (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Equity [Abstract]
Stock repurchased, Shares	2.6	4.3	13.1	15.9	6.9	28.9
Stock repurchased	$ 591	$ 933	$ 2,349	$ 3,031	$ 1,524	$ 5,380

Stockholders' equity (Details T

Stockholders' equity (Details Textual) (Details) - USD ($)	1 Months Ended				3 Months Ended
	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Class of Stock [Line Items]
Stock repurchase program, additional authorized amount				$ 4,000,000,000
Amount available for stock repurchases under a board approved stock repurchase plan		$ 4,900,000,000
Dividends declared per share (in usd per share)			$ 1.60	$ 1.60	$ 1.60	$ 1.45
Dividends paid per share (in usd per share)		$ 1.60	$ 1.60
Subsequent Event [Member]
Class of Stock [Line Items]
Dividends declared per share (in usd per share)	$ 1.60

Stockholders' equity (Component

Stockholders' equity (Components of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	$ 9,485	$ 9,673	$ 10,832	$ 9,673	$ 12,500
Foreign currency translation adjustments	(3)		(4)	(55)	(17)
Balance as of end of period	10,659	9,485	10,794	10,659	10,794
Foreign currency translation [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(770)	(718)		(718)
Foreign currency translation adjustments	(3)	(52)
Income taxes	0	0
Balance as of end of period	(773)	(770)		(773)
Cash flow hedges [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	114	175		175
Unrealized (losses) gains	(30)	(162)
Reclassification adjustments to income	(119)	84
Income taxes	(33)	(17)
Balance as of end of period	(2)	114		(2)
Available-for-sale securities [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	3	22		22
Unrealized (losses) gains	(2)	8
Reclassification adjustments to income	0	(33)
Income taxes	0	(6)
Balance as of end of period	1	3		1
Other [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(9)	(7)		(7)
Unrealized (losses) gains	0	0
Other	0	(2)
Balance as of end of period	(9)	(9)		(9)
AOCI [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(662)	(528)	(516)	(528)	(769)
Foreign currency translation adjustments	(3)	(52)
Unrealized (losses) gains	(32)	(154)
Reclassification adjustments to income	(119)	51
Other	0	(2)
Income taxes	33	23
Balance as of end of period	$ (783)	$ (662)	$ (465)	$ (783)	$ (465)

Stockholders' equity (Reclassif

Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	$ 3		$ 218		$ 14	$ 403
Income before income taxes	2,030		2,564		4,050	4,878
Provision for income taxes	(227)		(385)		(422)	(707)
Net income	1,803	$ 1,825	2,179	$ 1,992	3,628	4,171
Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	5,908		5,574		11,802	10,860
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes	119		36		35	8
Provision for income taxes	(26)		(8)		(8)	(2)
Net income	93		28		27	6
Reclassification out of Accumulated Other Comprehensive Income [Member] | Available-for-sale securities [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	0		(2)		33	(6)
Provision for income taxes	0		0		(7)	0
Net income	0		(2)		26	(6)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	68		22		117	36
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	51		14		(82)	(28)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	68		22		117	36
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	$ 51		$ 14		$ (82)	$ (28)

Fair value measurement (Details

Fair value measurement (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Assets:
Interest-bearing securities	$ 10,734	$ 8,234
Equity securities	297	303
Derivatives:
Total assets	11,415	9,086
Derivatives:
Contingent consideration obligations	55	61
Total liabilities	687	407
Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	236	224
Derivatives:
Foreign currency and cross-currency swap contracts	26	31
Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	27	66
Derivatives:
Foreign currency and cross-currency swap contracts	604	315
Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	121	259
Derivatives:
Interest rate swap contracts	2	0
Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Equity securities	297	303
Derivatives:
Total assets	11,029	5,913
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
Significant other observable inputs (Level 2) [Member]
Assets:
Equity securities	0	0
Derivatives:
Total assets	386	3,173
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	632	346
Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	236	224
Derivatives:
Foreign currency and cross-currency swap contracts	26	31
Significant other observable inputs (Level 2) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	27	66
Derivatives:
Foreign currency and cross-currency swap contracts	604	315
Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	121	259
Derivatives:
Interest rate swap contracts	2	0
Significant unobservable inputs (Level 3) [Member]
Assets:
Equity securities	0	0
Derivatives:
Total assets	0	0
Derivatives:
Contingent consideration obligations	55	61
Total liabilities	55	61
Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	175	360
U.S. Treasury notes [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	175	360
U.S. Treasury notes [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	0
U.S. Treasury notes [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	3,399	0
U.S. Treasury bills [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	3,399	0
U.S. Treasury bills [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	0
U.S. Treasury bills [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	0	1,121
Corporate debt securities - Financial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Financial [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	1,121
Corporate debt securities - Financial [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	2	834
Corporate debt securities - Industrial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Industrial [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	2	834
Corporate debt securities - Industrial [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	0	198
Corporate debt securities - Other [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Other [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	198
Corporate debt securities - Other [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	0	182
Residential mortgage-backed securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Residential mortgage-backed securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	182
Residential mortgage-backed securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Money market mutual funds [Member]
Assets:
Interest-bearing securities	7,158	5,250
Money market mutual funds [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	7,158	5,250
Money market mutual funds [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	0
Money market mutual funds [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	0	289
Other short-term interest-bearing securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Other short-term interest-bearing securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	289
Other short-term interest-bearing securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	$ 0	$ 0

Fair value measurement (Detai_2

Fair value measurement (Details Textual) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Length of time hedged in foreign currency contracts (or less)	3 years
Long-term debt, fair value	$ 40,000	$ 33,700
Carrying value of debt	$ 34,224	$ 29,903

Derivative instruments (Details

Derivative instruments (Details Textual) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Net cash provided by operating activities		$ 4,976	$ 3,259
Foreign currency and cross currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps		95
Derivatives designated as hedging instrument [Member] | Foreign currency forward contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount		5,000		$ 5,000
Derivatives designated as hedging instrument [Member] | Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount		7,400		9,600
Value of derivative contracts terminated		2,200
Value of derivative contracts terminated resulting in net cash provided by operating activities		5,200
Net cash provided by operating activities	$ 576	576
Derivatives not designated as hedging instrument [Member] | Foreign currency forward contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount		1,300		1,200
Interest Expense, Net [Member] | Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain recognized from termination of contracts		17
Long-term debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Hedged Liability, Fair Value Hedge		7,816		$ 8,814
Long-term debt [Member] | Interest Rate Swap, At-Then Current Interest Rates [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Hedged Liability, Fair Value Hedge		$ 5,200

Derivative instruments (Cross-c

Derivative instruments (Cross-currency Swaps) (Details) - Cash flow hedge [Member] - Cross-currency swap contracts [Member] € in Millions, £ in Millions, SFr in Millions, $ in Millions	Jun. 30, 2020USD ($)	Jun. 30, 2020EUR (€)	Jun. 30, 2020CHF (SFr)	Jun. 30, 2020GBP (£)
1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Notional amounts	$ 1,388	€ 1,250
0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Notional amounts	704		SFr 700
2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Notional amounts	833	€ 750
5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Notional amounts	747			£ 475
4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Notional amounts	$ 1,111			£ 700
Euro Member Countries, Euro | 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	1.30%	1.30%	1.30%	1.30%
Euro Member Countries, Euro | 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	2.00%	2.00%	2.00%	2.00%
Switzerland, Francs | 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	0.40%	0.40%	0.40%	0.40%
United Kingdom, Pounds | 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	5.50%	5.50%	5.50%	5.50%
United Kingdom, Pounds | 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.00%	4.00%	4.00%	4.00%
United States of America, Dollars | 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.20%	3.20%	3.20%	3.20%
United States of America, Dollars | 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	3.40%	3.40%	3.40%	3.40%
United States of America, Dollars | 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.90%	3.90%	3.90%	3.90%
United States of America, Dollars | 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	6.00%	6.00%	6.00%	6.00%
United States of America, Dollars | 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.50%	4.50%	4.50%	4.50%

Derivative instruments (Effecti

Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains (losses)	$ (30)	$ (96)	$ (192)	$ (66)
Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains (losses)	(101)	(16)	138	69
Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains (losses)	$ 71	$ (80)	$ (330)	$ (135)

Derivative instruments (Hedged

Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Derivative [Line Items]
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	$ 678	$ 296
Current portion of long-term debt [Member]
Derivative [Line Items]
Hedged Liability, Fair Value Hedge	89	903
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	89	4
Carrying value with discontinued hedging relationships	89
Hedging adjustments on discontinued hedging relationships	89
Long-term debt [Member]
Derivative [Line Items]
Hedged Liability, Fair Value Hedge	7,816	8,814
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	589	292
Carrying value with discontinued hedging relationships	569	136
Hedging adjustments on discontinued hedging relationships	$ 469	$ 36

Derivative instruments (Summary

Derivative instruments (Summary of Income and Expense Line Items) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	$ 3	$ 218	$ 14	$ 403
Interest expense, net	(296)	(332)	(642)	(675)
Interest rate swap agreements [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) on fair value hedging relationships, Hedged items	(30)	(218)	180	(348)
Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments	53	218	(137)	351
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	51	14	(82)	(28)
Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	5,908	5,574	11,802	10,860
Product sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	$ 68	$ 22	$ 117	$ 36

Derivative instruments (Fair Va

Derivative instruments (Fair Value of Derivatives) (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Assets
Total derivative assets, fair value	$ 384	$ 549
Liabilities
Total derivative liabilities, fair value	632	346
Derivatives designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	384	548
Liabilities
Total derivative liabilities, fair value	632	346
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	236	223
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	26	31
Derivatives designated as hedging instrument [Member] | Cross-currency swap contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	27	66
Derivatives designated as hedging instrument [Member] | Cross-currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	604	315
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	121	259
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	2	0
Derivatives not designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	0	1
Liabilities
Total derivative liabilities, fair value	0	0
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets [Member]
Assets
Total derivative assets, fair value	0	1
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities [Member]
Liabilities
Total derivative liabilities, fair value	$ 0	$ 0

Contingencies and commitments (

Contingencies and commitments (Details) - patent	Jun. 30, 2020	May 08, 2020
Loss Contingencies [Line Items]
Number of asserted patents expired		3
Humira Biosimilar Antitrust Class Actions [Member]
Loss Contingencies [Line Items]
Loss Contingency, appeal period	30 days